Datapoint: Viatris Sells Biosimilar Business to Biocon

Viatris, the manufacturer of the first interchangeable biosimilar, on Monday revealed it will sell its biosimilar business to partner Biocon Biologics in a $3.3 billion deal. This includes Semglee, the insulin interchangeable with Sanofi’s Lantus. The drug launched in November 2021. For the treatment of type 2 diabetes, Semglee currently holds covered or better status for 59% of all insured lives, to Lantus’ 70%.

SOURCE: MMIT Analytics, as of 3/1/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 22

Datapoint: Baystate to Sell Health Plan to Point32Health

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today